Geode Capital Management LLC Has $6.77 Million Stake in Savara Inc. $SVRA

Geode Capital Management LLC lifted its position in Savara Inc. (NASDAQ:SVRA) by 5.2% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,970,183 shares of the company’s stock after buying an additional 147,946 shares during the quarter. Geode Capital Management LLC’s holdings in Savara were worth $6,773,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the business. May Hill Capital LLC bought a new stake in Savara in the second quarter worth approximately $32,000. Brooklyn Investment Group bought a new stake in Savara in the first quarter worth $65,000. Los Angeles Capital Management LLC acquired a new position in Savara during the second quarter worth $69,000. Stonepine Capital Management LLC acquired a new stake in shares of Savara in the first quarter worth about $81,000. Finally, Farther Finance Advisors LLC lifted its position in shares of Savara by 17.6% in the second quarter. Farther Finance Advisors LLC now owns 38,001 shares of the company’s stock worth $87,000 after buying an additional 5,687 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Trading Up 2.0%

Shares of SVRA stock opened at $6.50 on Friday. Savara Inc. has a 1 year low of $1.89 and a 1 year high of $6.61. The firm’s fifty day simple moving average is $4.34 and its 200 day simple moving average is $3.30. The firm has a market capitalization of $1.32 billion, a P/E ratio of -12.26 and a beta of 0.23. The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.32.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). As a group, sell-side analysts predict that Savara Inc. will post -0.45 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on SVRA shares. Wells Fargo & Company started coverage on Savara in a research note on Monday, October 20th. They issued an “overweight” rating and a $7.00 price objective on the stock. HC Wainwright lifted their price target on shares of Savara from $5.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, September 3rd. Guggenheim boosted their price objective on shares of Savara from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, September 9th. Lifesci Capital upgraded shares of Savara to a “strong-buy” rating in a research note on Tuesday, October 14th. Finally, Wall Street Zen upgraded shares of Savara from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $8.29.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.